ReviewSAGE open medicine2024
An updated review on Guillain-Barré syndrome: Challenges in infection prevention and control in low- and middle-income countries.
Review in SAGE open medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Increasing Incidence of Guillain-Barré Syndrome in the USA among Integrated Delivery Systems from 2017 to 2023: Trends by Age and Charlson Comorbidity Index Score.Neuroepidemiology · 2026Article
- Guillain-Barré Syndrome Following Dengue Infection: A Case Series with Review of Literature.Annals of neurosciences · 2026Article
- The Role of Serum Albumin as a Prognostic Marker in Guillain-Barré Syndrome: A Systematic Review.Journal of inflammation research · 2026Review
- Guillain-Barré syndrome and albuminocytological dissociation: a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Patient Experiences of the Biopsychosocial Impact of Guillain-Barré Syndrome: A Scoping Review.Patient preference and adherence · 2025Review
- Complete genome sequence ofMicrobiology resource announcements · 2024Article
- Article
- Causal relationship between immune cells and Guillain-Barré syndrome: a Mendelian randomization study.Frontiers in neurology · 2024Article
- Guillain-Barré Syndrome Presenting With New-Onset Heart Failure.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guillain-Barré syndrome is a rare condition that can be potentially life-threatening. Guillain-Barré syndrome does not have a definitive etiological agent. It is a syndrome that can arise from multiple factors, including various infectious diseases and immunizations. The severity of Guillain-Barré syndrome is exacerbated by these variables, especially in low-income and middle-income countries where healthcare systems are already constrained and struggle to meet the demands of other diseases. The primary aim of our article is to comprehensively examine the life-threatening nature and intensity of Guillain-Barré syndrome by assessing its etiology, progression, and prevalence in low- and middle-income nations while also considering global trends. Furthermore, we proposed the implementation of standard and efficacious treatment and diagnostic resources that are readily accessible and successful in affluent nations and should also be readily accessible in impoverished nations without any unnecessary delay. Our study also emphasized the epidemiological data with molecular epidemiological analysis and the utilization of artificial technology in low- and middle-income nations. The goal was to decrease the incidence of Guillain-Barré syndrome cases and facilitate early detection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.